Abstract
The concept of reverse immune surveillance, first conceived over 12 years ago, described the relationship that existed between germinal center-derived B cell lymphoma cells and the host immune system in SJL/J mice. According to reverse immune surveillance, recognition of tumor cell antigens and a response by the host immune system is required for tumor growth. The phenomenon of reverse immune surveillance related to B cell lymphomas has recently also been characterized in another inbred mouse strain, C57L/J. Moreover, elements of reverse immune surveillance have been observed in several other mouse strains that develop B cell lymphomas, suggesting that this lymphomagenic mechanism may be more common than first envisioned. In SJL and C57L mice, the B lymphoma cells express an MMTV-encoded superantigen (vSAg29) that stimulates syngeneic CD4+T cells bearing V β 16 in their TCR. In contrast to the mRNAs for other MMTVs in normal mouse B cells, vSAg29 mRNA initiates in the env(META) region, undergoes splicing in the 3′env region, and continues through the 3′LTR. Copious cytokine production, including IFN- γ, IL-4 and IL-5 accompanies the response of the T cells to this vSAg. In addition to cytokines produced by vSAg-responsive T cells, more recent evidence indicates that another cytokine, LT αβ 2, which is expressed on the lymphoma cell surface, also plays a role in the promotion of the B cell lymphoma growth. It is possible that interaction with LT β -R on follicular dendritic cells or other stromal elements facilitates tumor growth by preventing apoptosis of the malignant B cells. To what degree these findings in the mouse are relevant to the development and/or growth of human B lymphoma cells remains to be determined. However, endogenous retroviral sequences do exist in the human genome. Interestingly, some of these sequences are homologous to MMTV, and are transcribed in B lymphoblastoid cells. Moreover, microorganisms that are infectious for human B cells, such as EBV and Herpes Virus 8, may also produce superantigens.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.